Two statements can be true in the same quarter. The PBM met its generic effective rate guarantee. You lost money on a meaningful share of the generics you dispensed. Understanding why they are compatible is the difference between arguing about the right thing and arguing about the wrong one.
What the clause actually says
A generic effective rate (GER) commits the PBM to a plan sponsor that generic drug cost, measured across a defined claim population over a defined period, will average out to no worse than some percentage off AWP. A brand effective rate (BER) does the same for brands. The rate is usually expressed the way a per-claim rate would be, which is what makes it easy to misread.
Three details in the fine print do most of the work.
It is measured in aggregate, not per claim. The guarantee is a portfolio result. No individual claim has to land anywhere near it.
The measurement population is usually the network, not your store. Where a PSAO signed the agreement on your behalf, the book being measured is the PSAO’s, aggregating hundreds or thousands of pharmacies. Frier Levitt has written about the consequence: pharmacies carry the financial result of a reconciliation they had no input into and cannot independently verify.
Full cost typically includes the patient’s copay. GER is generally assessed on total drug cost, reimbursement plus copay, against AWP. A claim with a $40 copay and $3 of plan payment can contribute usefully to the PBM’s target while contributing almost nothing to you.
The arithmetic
Here is a five-claim basket. The figures are illustrative and chosen to show the mechanism.
| Claim | AWP | Ingredient cost paid | Implied discount | Net acquisition | Margin |
|---|---|---|---|---|---|
| A | $1,240.00 | $62.00 | AWP less 95.0% | $48.00 | $14.00 |
| B | $310.00 | $27.90 | AWP less 91.0% | $22.00 | $5.90 |
| C | $46.00 | $12.42 | AWP less 73.0% | $9.10 | $3.32 |
| D | $28.00 | $9.80 | AWP less 65.0% | $19.40 | ($9.60) |
| E | $19.50 | $8.19 | AWP less 58.0% | $16.25 | ($8.06) |
| Total | $1,643.50 | $120.31 | AWP less 92.68% | $5.56 |
Against a guarantee of AWP less 92.5 percent, this basket clears it. The PBM has met its commitment. Two of the five claims were dispensed below acquisition cost.
The reason is weighting. Claim A alone is 75 percent of the AWP in the basket. One high-AWP generic priced generously carries the average, and everything below it can be squeezed without endangering the guarantee. That is not an abuse of the clause. It is the clause working exactly as written.
Now invert it. If the network is trending at AWP less 90 percent halfway through the period, the PBM is behind its commitment and has one obvious lever: tighten MAC. Your rates move mid-period, no amendment arrives, and nothing in your contract has changed.
Where the true-up lands
Point-of-sale pricing is MAC. Reconciliation is separate and typically annual. If the network came in more generous than the guarantee, the PBM recovers the difference. Some contracts run this as a retrospective recoupment after the period closes. Others withhold at the point of sale throughout the year against an anticipated year-end reconciliation, which is effectively an escrow funded by your cash flow.
This is worth being precise about, because the 2024 Part D change is often misread as having ended all of it. CMS redefined the Part D negotiated price so that from 1 January 2024 all pharmacy price concessions must be reflected at the point of sale, with the negotiated price set at the lowest amount a pharmacy could receive under its contract. That addressed retroactive pharmacy DIR in Part D. It did not touch GER and BER reconciliation in commercial business, which continues to operate on the old pattern.
The regulatory direction of travel is toward more visibility. The Department of Labor’s proposed PBM fee disclosure rule, published in the Federal Register on 30 January 2026, would require providers of pharmacy benefit management services to disclose compensation to fiduciaries of self-insured ERISA plans, and the proposal explicitly contemplates disclosure of spread pricing revenue and amounts clawed back from pharmacies. That disclosure runs to the plan sponsor rather than to you, but it makes the mechanism harder to describe as commercially confidential.
Read the exclusions before you read the rate
The number in the clause matters less than the population it is measured over. Commonly excluded: specialty and limited distribution drugs, compounds, over-the-counter items, vaccines, 340B claims, secondary and coordination of benefits claims, claims with a zero plan payment, and single-source generics.
Each exclusion removes claims from the measured basket. Whether that helps or hurts you depends on which side of the average those claims sat. A contract that excludes exactly the categories where the PBM pays generously is measuring a different business than the one you run.
Also find the measurement period boundary and the reconciliation date. Those two facts explain most rate movements that otherwise look arbitrary, and they tell you when a recoupment can appear on a remittance.
What to measure on your side
Your own effective rate, computed the PBM’s way. Same formula, same exclusions, same treatment of copay. If you compute it differently you will get a number you cannot use in a conversation.
Per BIN and PCN, monthly. A single blended figure across all payers is not actionable. Rate tables are plan-level, so the analysis has to be too.
Dispersion, not just the mean. The mean is the PBM’s metric. Yours is the shape of the distribution. Ask what share of generic claims paid below net acquisition cost, and what those claims cost you in total. A basket averaging AWP less 92 percent with a long negative tail is a different business from one averaging the same with none.
Your mix against the network’s. You will not have the network’s mix, but you can spot the tell. If your realised rate is consistently worse than the guarantee, you are dispensing more of the categories the network is funding its average from.
What to do with it
The claims that lose money for contract reasons and the claims that lose money for purchasing reasons look identical on a profit and loss statement, and identical in any monthly gross margin percentage. Separating them requires the claim, the plan identifier and the true net acquisition cost in the same row, and it requires them while the MAC appeal window is still open, which at several PBMs is counted in business days from the initial claim rather than from the remittance.
Attergo Intelligence computes the effective rate per contract on the live claim stream and shows the dispersion behind it, which is the version of this analysis you can take into a renewal conversation. The underlying discipline is available to anyone willing to do the join: aggregate performance and claim-level performance are different questions, and a PBM answering the first one honestly has told you nothing about the second.